Axinn Obtains Favorable Decision in FDA Suit
January 15, 2013
Axinn secured a favorable outcome for client Alvogen Inc. in ViroPharma Inc’s case against the U.S. Food and Drug Administration regarding generic forms of the antibiotic Vancocin (vancomycin). The Axinn team assisted Alvogen Inc. in intervening on the side of the government in order to allow Alvogen to continue to market its generic vancomycin product under its approved Abbreviated New Drug Application.
Judge Huvelle’s Memorandum Opinion stated that “the FDA acted well within its discretion in denying three-year exclusivity to ViroPharma and in approving the ANDAs of intervenor-defendants.”
To subscribe to our publications, click here.
Featured Insights
Featured Insights
Consero Healthcare General Counsel Forum 2026
Sponsorship
Antitrust
Energizing Tomorrow: The Future of Energy, Antitrust & International Business Law
Sponsorship
Antitrust
IBA Annual Conference 2026
Sponsorship
Antitrust
CCWC 22nd Annual Career Strategies Conference
Sponsorship
Fordham Competition Law Institute's 53rd Annual Conference on International Antitrust Law and Policy, and Antitrust Economics Workshop
Sponsorship
Antitrust
Survival vs. Antitrust: Inside the FTC’s Strict Standards for "Failing" Hospital Acquisitions
Axinn Viewpoints
Antitrust
Women, Influence, & Power in Law Conference 2026
Sponsorship
Antitrust
IP Litigation North America Summit 2026
Sponsorship
Intellectual Property
Axinn Partners Named to Lawdragon’s 2027 500 “Leading Litigators in America” Guide
Awards & Recognitions
Antitrust
HNBA/VIA Annual Convention 2026
Sponsorship
Antitrust
